Loading…
RPG Life Sciences (RPGLIFE)₹2,596+0.66%Pharmaceuticals
In the Sep 2026 quarter (consolidated), RPG Life Sciences reported sales of ₹212 Cr, up 16.4% from Sep 2025, and net profit of ₹28.02 Cr, down 24.3% year on year. For the year to Mar 2026, sales were ₹708 Cr and net profit ₹115 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 173 | 143 | 169 | 182 | 180 | 177 | 196 | 212 |
| Expenses | 124 | 118 | 133 | 144 | 141 | 145 | 153 | 172 |
| Operating Profit | 48.88 | 24.93 | 34.88 | 38.88 | 39.89 | 32.92 | 43.88 | 39.91 |
| OPM % | 27.9% | 18.0% | 20.9% | 21.0% | 21.9% | 18.9% | 21.9% | 18.9% |
| Other Income | 3.01 | 115 | 5.01 | 16.03 | −5.01 | 14.04 | 4.01 | 4.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 |
| Depreciation | 5.01 | 5.01 | 4.99 | 5.01 | 4.99 | 6.01 | 5.99 | 6.99 |
| Profit before tax | 46.98 | 135 | 34.97 | 48.94 | 28.97 | 39.98 | 40.93 | 36.99 |
| Tax % | 26.0% | 13.0% | 26.0% | 25.0% | 24.0% | 26.0% | 26.0% | 24.0% |
| Exceptional items | 0.00 | 95.67 | 0.00 | 8.35 | −6.39 | 0.83 | 0.00 | 0.00 |
| Net Profit | 35.01 | 117 | 26.03 | 37.02 | 22.02 | 29.99 | 31.03 | 28.02 |
| EPS (Rs) | 21.19 | 71.26 | 15.97 | 22.35 | 13.44 | 18.16 | 18.57 | 16.14 |
| Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|
| Sales | 653 | 708 | 765 |
| Expenses | 495 | 563 | 610 |
| Operating Profit | 161 | 148 | 157 |
| OPM % | 25.0% | 20.9% | 20.5% |
| Other Income | 95.19 | 29.09 | 17.05 |
| Interest | 2.01 | 2.01 | 2.02 |
| Depreciation | 21.01 | 21.01 | 23.98 |
| Profit before tax | 233 | 154 | 147 |
| Tax % | 21.0% | 25.0% | — |
| Exceptional items | 68.05 | 6.01 | −5.56 |
| Net Profit | 183 | 115 | 111 |
| EPS (Rs) | 111.27 | 69.94 | 66.31 |
| Dividend payout % | 22.0% | 34.0% | — |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 13.05 | 13.06 |
| Reserves | 517 | 593 |
| Borrowings | 0.00 | 20.04 |
| Other Liabilities | 128 | 169 |
| Total Liabilities | 659 | 795 |
| Fixed Assets | 172 | 197 |
| CWIP | 15.99 | 22.97 |
| Investments | 127 | 85.04 |
| Other Assets | 344 | 490 |
| Inventories | 92.70 | 124 |
| Trade receivables | 87.27 | 117 |
| Cash & equivalents | 140 | 192 |
| Total Assets | 659 | 795 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from operating activity | 77.83 | 55.87 |
| Cash from investing activity | −42.08 | 86.25 |
| Cash from financing activity | −26.97 | −20.97 |
| Net cash flow | 9.02 | 122 |
| Capex | 35.87 | 64.85 |
| Free cash flow | 151 | −8.98 |
| CFO / OP % | 81.0% | 63.0% |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor days | 49 | 61 |
| Inventory days | 160 | 180 |
| Days payable | 136 | 142 |
| Cash conversion cycle | 72 | 99 |
| Working capital days | 44 | 63 |
| ROCE % | — | 26.0% |
For the Sep 2026 quarter, RPG Life Sciences reported sales of ₹212 Cr, up 16.4% year on year and net profit of ₹28.02 Cr, down 24.3% year on year. The operating margin was 18.9%.
RPG Life Sciences' sales for the year to Mar 2026 were ₹708 Cr; over the last twelve months they were ₹765 Cr.
Net profit for the year to Mar 2026 was ₹115 Cr, and ₹111 Cr over the last twelve months. Earnings per share over the same trailing period were ₹66.31.
RPG Life Sciences reported borrowings of ₹20.04 Cr at Mar 2026, against cash and equivalents of ₹192 Cr.
Cash from operations was ₹55.87 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹8.98 Cr.